{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:07:14Z","timestamp":1792465634642,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40266-018-0603-x","type":"journal-article","created":{"date-parts":[[2018,10,28]],"date-time":"2018-10-28T21:02:56Z","timestamp":1540760576000},"page":"1031-1040","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Recombinant Zoster Vaccine (Shingrix\u00ae): A Review in Herpes Zoster"],"prefix":"10.1007","volume":"35","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"issue":"3","key":"603_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369(3):255\u201363.","journal-title":"N Engl J Med."},{"key":"603_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.07.099","author":"S Esposito","year":"2017","unstructured":"Esposito S, Principi N. Herpes zoster prevention: a difficult problem to solve. Vaccine. 2017. https:\/\/doi.org\/10.1016\/j.vaccine.2017.07.099.","journal-title":"Vaccine."},{"issue":"4","key":"603_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109\u201320.","journal-title":"Ther Adv Vaccines."},{"issue":"8","key":"603_CR4","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/j.1525-1497.2005.0150.x","volume":"20","author":"RP Insinga","year":"2005","unstructured":"Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748\u201353.","journal-title":"J Gen Intern Med."},{"key":"603_CR5","unstructured":"GSK. Shingrix (zoster vaccine recombinant, adjuvanted): US prescribing information. 2017. https:\/\/www.fda.gov. Accessed 16 Aug 2018."},{"key":"603_CR6","unstructured":"European Medicines Agency. Shingrix, herpes zoster vaccine (recombinant, adjuvanted): summary of product characteristics. 2018. http:\/\/www.ema.europa.eu. Accessed 16 Aug 2018."},{"issue":"3","key":"603_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40259-016-0180-7","volume":"30","author":"GM Keating","year":"2016","unstructured":"Keating GM. Shingles (herpes zoster) vaccine (Zostavax\u00ae): a review in the prevention of herpes zoster and postherpetic neuralgia. BioDrugs. 2016;30(3):243\u201354.","journal-title":"BioDrugs."},{"key":"603_CR8","first-page":"CD008858","volume":"3","author":"AM Gagliardi","year":"2016","unstructured":"Gagliardi AM, Andriolo BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2016;3:CD008858.","journal-title":"Cochrane Database Syst Rev."},{"key":"603_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020528","author":"EA Yanni","year":"2018","unstructured":"Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000\u20132012. BMJ Open. 2018. https:\/\/doi.org\/10.1136\/bmjopen-2017-020528.","journal-title":"BMJ Open."},{"issue":"7","key":"603_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14760584.2018.1495565","volume":"17","author":"N Lecrenier","year":"2018","unstructured":"Lecrenier N, Beukelaers P, Colindres R, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619\u201334.","journal-title":"Expert Rev Vaccines."},{"issue":"8","key":"603_CR11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1080\/21645515.2017.1317410","volume":"13","author":"T Bharucha","year":"2017","unstructured":"Bharucha T, Ming D, Breuer J. A critical appraisal of \u2018Shingrix\u2019, a novel herpes zoster subunit vaccine (HZ\/Su or GSK1437173A) for varicella zoster virus. Hum Vaccines Immunother. 2017;13(8):1789\u201397.","journal-title":"Hum Vaccines Immunother."},{"issue":"4","key":"603_CR12","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.1400948","volume":"193","author":"AM Didierlaurent","year":"2014","unstructured":"Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920\u201330.","journal-title":"J Immunol."},{"issue":"20","key":"603_CR13","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","volume":"30","author":"N Dendouga","year":"2012","unstructured":"Dendouga N, Fochesato M, Lockman L, et al. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30(20):3126\u201335.","journal-title":"Vaccine."},{"issue":"11","key":"603_CR14","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham AL, Heineman TC, Lal H, et al. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50\u00a0years or older. J Infect Dis. 2018;217(11):1750\u201360.","journal-title":"J Infect Dis."},{"issue":"48 Pt B","key":"603_CR15","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1016\/j.vaccine.2017.10.017","volume":"35","author":"A Strezova","year":"2017","unstructured":"Strezova A, Godeaux O, Aggarwal N, et al. A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ\/su. Vaccine. 2017;35(48 Pt B):6700\u20136.","journal-title":"Vaccine."},{"issue":"1","key":"603_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","volume":"36","author":"H Lal","year":"2018","unstructured":"Lal H, Poder A, Campora L, et al. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12\u00a0months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36(1):148\u201354.","journal-title":"Vaccine."},{"issue":"11","key":"603_CR17","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/infdis\/jix481","volume":"216","author":"TF Schwarz","year":"2017","unstructured":"Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50\u00a0years or older. J Infect Dis. 2017;216(11):1352\u201361.","journal-title":"J Infect Dis."},{"issue":"11","key":"603_CR18","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/infdis\/jix482","volume":"216","author":"K Grupping","year":"2017","unstructured":"Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ\/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017;216(11):1343\u201351.","journal-title":"J Infect Dis."},{"issue":"5","key":"603_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/21645515.2016.1265715","volume":"13","author":"O Godeaux","year":"2017","unstructured":"Godeaux O, Kovac M, Shu D, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults\u2009\u2265\u200950\u00a0years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Hum Vaccines Immunother. 2017;13(5):1051\u20138.","journal-title":"Hum Vaccines Immunother."},{"issue":"3","key":"603_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1080\/21645515.2016.1232787","volume":"13","author":"P Vink","year":"2017","unstructured":"Vink P, Shiramoto M, Ogawa M, et al. Safety and immunogenicity of a herpes zoster subunit vaccine in Japanese population aged \u2265 50 years when administered subcutaneously vs. intramuscularly. Hum Vaccines Immunother. 2017;13(3):574\u20138.","journal-title":"Hum Vaccines Immunother."},{"issue":"15","key":"603_CR21","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.vaccine.2014.01.019","volume":"32","author":"R Chlibek","year":"2014","unstructured":"Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745\u201353.","journal-title":"Vaccine."},{"issue":"12","key":"603_CR22","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/infdis\/jit365","volume":"208","author":"R Chlibek","year":"2013","unstructured":"Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults\u2009\u2265\u200950\u00a0years of age. J Infect Dis. 2013;208(12):1953\u201361.","journal-title":"J Infect Dis."},{"issue":"7","key":"603_CR23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.4161\/hv.24269","volume":"9","author":"H Lal","year":"2013","unstructured":"Lal H, Zahaf T, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ\/su): a phase-I, open-label study in Japanese adults. Hum Vaccines Immunother. 2013;9(7):1425\u20139.","journal-title":"Hum Vaccines Immunother."},{"issue":"29","key":"603_CR24","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","volume":"36","author":"C Marechal","year":"2018","unstructured":"Marechal C, Lal H, Poder A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults\u2009\u2265\u200950\u00a0years of age: a randomized trial. Vaccine. 2018;36(29):4278\u201386.","journal-title":"Vaccine."},{"issue":"8","key":"603_CR25","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/infdis\/jis497","volume":"206","author":"I Leroux-Roels","year":"2012","unstructured":"Leroux-Roels I, Leroux-Roels G, Clement F, et al. A phase 1\/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206(8):1280\u201390.","journal-title":"J Infect Dis."},{"issue":"6","key":"603_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.vaccine.2015.09.073","volume":"34","author":"R Chlibek","year":"2016","unstructured":"Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863\u20138.","journal-title":"Vaccine."},{"issue":"6","key":"603_CR27","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","volume":"14","author":"TF Schwarz","year":"2018","unstructured":"Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccines Immunother. 2018;14(6):1370\u20137.","journal-title":"Hum Vaccines Immunother."},{"issue":"Suppl. 1","key":"603_CR28","first-page":"S172","volume":"7","author":"J Diez-Domingo","year":"2016","unstructured":"Diez-Domingo J, Kovac M, Vesikari T, et al. Efficacy and immunogenicity of an investigational subunit adjuvanted herpes zoster vaccine in older adults in Europe: results from the ZOE-50 and ZOE-70 efficacy studies [abstract no. P543]. Eur Geriatr Med. 2016;7(Suppl. 1):S172.","journal-title":"Eur Geriatr Med."},{"key":"603_CR29","unstructured":"US FDA. Shingrix (zoster vaccine recombinant, adjuvanted): FDA briefing document. 2017. https:\/\/www.fda.gov. Accessed 16 Aug 2018."},{"issue":"22","key":"603_CR30","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396.","journal-title":"N Engl J Med."},{"issue":"11","key":"603_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70\u00a0years of age or older. N Engl J Med. 2016;375(11):1019\u201332.","journal-title":"N Engl J Med."},{"issue":"10","key":"603_CR32","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, et al. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccines Immunother. 2017;13(10):2213\u201321.","journal-title":"Hum Vaccines Immunother."},{"issue":"12","key":"603_CR33","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.vaccine.2018.02.029","volume":"36","author":"M Kovac","year":"2018","unstructured":"Kovac M, Lal H, Cunningham AL, et al. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36(12):1537\u201341.","journal-title":"Vaccine."},{"key":"603_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gly150","author":"D Curran","year":"2018","unstructured":"Curran D, Oostvogels L, Heineman T, et al. Quality of life impact of a recombinant zoster vaccine in adults \u2265 50 years of age. J Gerontol A Biol Sci Med Sci. 2018. https:\/\/doi.org\/10.1093\/gerona\/gly150.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"3","key":"603_CR35","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/ajt.14683","volume":"18","author":"KL Dooling","year":"2018","unstructured":"Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. Am J Transplant. 2018;18(3):756\u201362.","journal-title":"Am J Transplant."},{"issue":"7","key":"603_CR36","first-page":"1777","volume":"12","author":"S Esposito","year":"2016","unstructured":"Esposito S, Bonanni P, Maggi S, et al. Recommended immunization schedules for adults: clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccines Immunother. 2016;12(7):1777\u201394.","journal-title":"Hum Vaccines Immunother."},{"key":"603_CR37","unstructured":"Ottawa Public Health. Immunization update: NACI recommends RZV (Shingrix\u00ae) vaccine in persons aged 50\u00a0years and older. 2018. https:\/\/www.ottawapublichealth.ca. Accessed 16 Aug 2018."},{"issue":"6","key":"603_CR38","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1086\/528696","volume":"197","author":"MJ Levin","year":"2008","unstructured":"Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825\u201335.","journal-title":"J Infect Dis."},{"key":"603_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/jci121484","author":"MJ Levin","year":"2018","unstructured":"Levin MJ, Kroehl ME, Johnson MJ, et al. Th1 memory differentiates recombinant from live herpes zoster vaccines. J Clin Investig. 2018. https:\/\/doi.org\/10.1172\/jci121484.","journal-title":"J Clin Investig."},{"key":"603_CR40","doi-asserted-by":"crossref","unstructured":"Oostvogels L, Zoster-039 Study Group. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: a phase III, randomized clinical trial [abstract no. 1344 plus poster]. In: IDWeek 2017.","DOI":"10.1093\/ofid\/ofx163.1040"},{"key":"603_CR41","doi-asserted-by":"crossref","unstructured":"Vink P, Zoster-039 Study Group. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine in adults with solid tumors vaccinated before or during immunosuppressive chemotherapy treatment: a phase II\/III, randomized clinical trial [abstract no. 1349 plus poster]. In: IDWeek 2017.","DOI":"10.1093\/ofid\/ofx163.1045"},{"key":"603_CR42","doi-asserted-by":"crossref","unstructured":"Vink P, Zoster-041 Study group. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine (HZ\/su) in adults post renal transplant: a phase III randomized clinical trial [abstract no. 1348 plus poster]. In: IDWeek 2017.","DOI":"10.1093\/ofid\/ofx163.1044"},{"key":"603_CR43","unstructured":"Sullivan K, Abhyankar S, Campora L, et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine in adult autologous hematopoietic stem cell transplant recipients: phase 3, randomized, placebo-controlled, ZOE-HSCT clinical trial [abstract]. In: 44th annual meeting of the European Society for Blood and Marrow Transplantation. 2018."},{"issue":"8","key":"603_CR44","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/infdis\/jiu606","volume":"211","author":"EM Berkowitz","year":"2015","unstructured":"Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279\u201387.","journal-title":"J Infect Dis."},{"issue":"19","key":"603_CR45","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","volume":"124","author":"EA Stadtmauer","year":"2014","unstructured":"Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921\u20139.","journal-title":"Blood."},{"issue":"9","key":"603_CR46","doi-asserted-by":"publisher","first-page":"A780","DOI":"10.1016\/j.jval.2017.08.2265","volume":"20","author":"H Burnett","year":"2017","unstructured":"Burnett H, McGirr A, Widenmaier R, et al. Vaccines for herpes zoster: a systematic review of randomized controlled trials in adults \u2265 50 years of age [abstract no. PIN12 and poster]. Value Health. 2017;20(9):A780.","journal-title":"Value Health."},{"issue":"2","key":"603_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/21645515.2017.1264831","volume":"13","author":"G Gabutti","year":"2017","unstructured":"Gabutti G, Bonanni P, Conversano M, et al. Prevention of herpes zoster and its complications: from clinical evidence to real life experience. Hum Vaccines Immunother. 2017;13(2):391\u20138.","journal-title":"Hum Vaccines Immunother."},{"key":"603_CR48","unstructured":"de la Serna J, Campora L, Chandrasekar P, et al. Efficacy and safety of an adjuvanted herpes zoster subunit vaccine in autologous hematopoietic stem cell transplant recipients 18\u00a0years of age or older: first results of the phase 3 randomized, placebo-controlled ZOE-HSCT clinical trial [abstract]. In: 2018 blood and marrow transplantation tandem meetings."},{"issue":"33","key":"603_CR49","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345.","journal-title":"Vaccine."},{"key":"603_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1509645","author":"D Van Oorschot","year":"2018","unstructured":"Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged \u2265 60 years old. Hum Vaccines Immunother. 2018. https:\/\/doi.org\/10.1080\/21645515.2018.1509645.","journal-title":"Hum Vaccines Immunother."},{"issue":"9","key":"603_CR51","doi-asserted-by":"publisher","first-page":"A520","DOI":"10.1016\/j.jval.2017.08.687","volume":"20","author":"DA Van Oorschot","year":"2017","unstructured":"Van Oorschot DA, Loiacono I, Pitrelli A, et al. Forecasting the potential public health impact of herpes zoster vaccination in Italy [abstract no. PIH4]. Value Health. 2017;20(9):A520.","journal-title":"Value Health."},{"issue":"7","key":"603_CR52","first-page":"A400","volume":"19","author":"DA Van Oorschot","year":"2016","unstructured":"Van Oorschot DA, Hunjan M, Varghese L, et al. The public health perspective of an investigational herpes zoster vaccine in the United Kingdom (UK) [abstract no. PIH5 and poster]. Value Health. 2016;19(7):A400.","journal-title":"Value Health."}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-018-0603-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0603-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0603-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:17:02Z","timestamp":1659086222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-018-0603-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":52,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0603-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"29 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yahiya Y. Syed is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}